Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Eptinezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck Files for Marketing Authorization Across for Vyepti
    Lundbeck Files for Marketing Authorization Across for Vyepti

    14 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html

    PR NEWSWIRE
    14 Nov 2025
    Share Share
    Lundbeck Shows Vyepti Long-Term Migraine Prevention Efficacy
    Lundbeck Shows Vyepti Long-Term Migraine Prevention Efficacy

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-showcases-new-clinical-migraine-data-including-long-term-preventive-effectiveness-of-vyepti-eptinezumab-in-patients-severely-impacted-by-migraine-302553629.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005030/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.

    21 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119

    FDA
    21 Oct 2022
    Share Share
    Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
    Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag

    19 Aug 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/setback-lundbeck-cgrp-migraine-drug-vyepti-hits-expansion-snag-sales-still-doubled

    Angus Liu FIERCEPHARMA
    19 Aug 2022
    Share Share
    Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine
    Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine

    09 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220609005304/en

    BUSINESSWIRE
    09 Jun 2022
    Share Share